All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS resp ...
Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback